Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. (December 2018)

• Record Type: Journal Article
• Authors: McDermott, David; Huseni, Mahrukh; Atkins, Michael; Motzer, Robert; Rini, Brian; Escudier, Bernard; Fong, Lawrence; Joseph, Richard; Pal, Sumanta; Reeves, James; Sznol, Mario; Hainsworth, John; Rathmell, W.; Stadler, Walter; Hutson, Thomas; Gore, Martin; Ravaud, Alain; Bracarda, Sergio; Suárez, Cristina; Danielli, Riccardo; Gruenwald, Viktor; Choueiri, Toni; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth; Thobhani, Alpa; Qiu, Jiaheng; Chen, Daniel; Hegde, Priti; Schiff, Christina; Fine, Gregg; Powles, Thomas;
• Is Part Of: Nature medicine. Volume 24:Number 12(2018)
• Page Start: 1941
• Page End: 1941
• Publication Date: 2018-12
• Subjects: Pathology, Molecular -- Periodicals; Molecular biology -- Periodicals; 610.724
• DOI: 10.1038/s41591-018-0235-z
• Languages: English
• ISSNs: 1078-8956

Abstract

In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF versions of this article.